Skip to main content

Table 1 Clinical characteristics of patients and controls

From: Dimethylarginines in patients with intracerebral hemorrhage: association with outcome, hematoma enlargement, and edema

 

ICH (n = 20)

Controls (n = 30)

P

Female

11 (55.0)

17 (56.7)

0.907

Male

9 (45.0)

13 (43.3)

 

Age (years)

77 (72; 84)

71 (63; 76)

0.106

Hypertension

15 (75.0)

24 (80.0)

0.676

Smoker

1 (5.0)

4 (13.3)

0.336

Hyperlipoproteinemia

6 (30.0)

15 (50.0)

0.160

Diabetes mellitus

1 (5.0)

4 (13.3)

0.336

History of CVD

0 (0.0)

3 (10.0)

0.145

History of CHD

1 (5.0)

5 (16.7)

0.214

History of antiplatelets

4 (20.0)

9 (30.0)

0.430

History of anticoagulants

1 (5.0)

0 (0.0)

0.216

eGFR (ml/min per 1.73 m2)

86.9 (65.4; 98.2)

70.7 (61.7; 86.6)

0.104

NIHSS on admission

9 (6; 15)

n.a.

–

mRS 90 days

3 (2; 4)

n.a.

–

Deep location of ICH

15 (75.0)

n.a.

–

IVH extension

2 (10.0)

n.a.

–

Hematoma volume (ml)

10.3 (3.1; 24.4)

n.a.

–

Hematoma enlargement

5 (25.0)

n.a.

–

Perihematomal edema (ml)

23.0 (11.9; 61.5)

n.a.

–

Cytotoxic edema

9 (45.0)

n.a.

–

  1. Data are presented as numbers (percentages) or median (interquartile range). P < 0.05 was considered statistically significant
  2. CHD coronary heart disease, CVD cerebrovascular disease, eGFR estimated glomerular filtration rate, IVH intraventricular hematoma, mRS modified Rankin Scale, NIHSS National Institutes of Health Stroke Scale
Back to article page

Journal of Neuroinflammation

ISSN: 1742-2094